Piper Jaffray said the FDA's statement warning against the use of Teva's (TEVA) liquid form of Treanda with certain devices creates a sense of urgency for Teva to have Eagle Pharmaceuticals' (EGRX) rapid infusion form of bendamustine, EP-3102, available and is positive for the regulatory landscape for EP-3102 as well. The firm raised its price target on Eagle to $51 from $41 and reiterates its Overweight rating on the shares.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."